FR2877571B1 - Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations - Google Patents

Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations

Info

Publication number
FR2877571B1
FR2877571B1 FR0411806A FR0411806A FR2877571B1 FR 2877571 B1 FR2877571 B1 FR 2877571B1 FR 0411806 A FR0411806 A FR 0411806A FR 0411806 A FR0411806 A FR 0411806A FR 2877571 B1 FR2877571 B1 FR 2877571B1
Authority
FR
France
Prior art keywords
nanoparticles
preparation
targeting element
intracellular targeting
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0411806A
Other languages
English (en)
Other versions
FR2877571A1 (fr
Inventor
Laurent Levy
Abdel Kader Boussaha
Edouard Andre Panak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanobiotix SA
Original Assignee
Nanobiotix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix SA filed Critical Nanobiotix SA
Priority to FR0411806A priority Critical patent/FR2877571B1/fr
Priority to US11/666,672 priority patent/US20070292353A1/en
Priority to JP2007539611A priority patent/JP5224814B2/ja
Priority to PCT/FR2005/002758 priority patent/WO2006051198A1/fr
Priority to EP05815304A priority patent/EP1807115A1/fr
Publication of FR2877571A1 publication Critical patent/FR2877571A1/fr
Application granted granted Critical
Publication of FR2877571B1 publication Critical patent/FR2877571B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Ceramic Engineering (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
FR0411806A 2004-11-05 2004-11-05 Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations Expired - Fee Related FR2877571B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0411806A FR2877571B1 (fr) 2004-11-05 2004-11-05 Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
US11/666,672 US20070292353A1 (en) 2004-11-05 2005-11-04 Nanoparticles Comprising an Intracellular Targeting Element and Preparation and Use Thereof
JP2007539611A JP5224814B2 (ja) 2004-11-05 2005-11-04 細胞内ターゲティングエレメントを含んでなるナノ粒子、その調製および使用
PCT/FR2005/002758 WO2006051198A1 (fr) 2004-11-05 2005-11-04 Nanoparticules pourvues d'un element de ciblage intra-cellulaire, preparation et utilisations
EP05815304A EP1807115A1 (fr) 2004-11-05 2005-11-04 Nanoparticules pourvues d'un element de ciblage intra-cellulaire, preparation et utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0411806A FR2877571B1 (fr) 2004-11-05 2004-11-05 Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations

Publications (2)

Publication Number Publication Date
FR2877571A1 FR2877571A1 (fr) 2006-05-12
FR2877571B1 true FR2877571B1 (fr) 2007-04-13

Family

ID=34953753

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0411806A Expired - Fee Related FR2877571B1 (fr) 2004-11-05 2004-11-05 Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations

Country Status (5)

Country Link
US (1) US20070292353A1 (fr)
EP (1) EP1807115A1 (fr)
JP (1) JP5224814B2 (fr)
FR (1) FR2877571B1 (fr)
WO (1) WO2006051198A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
JP4911915B2 (ja) * 2005-05-09 2012-04-04 トヨタ自動車株式会社 標的物の分解方法及び分解装置
US9493817B2 (en) * 2007-03-05 2016-11-15 Genesis Research Institute, Inc. Decomposition method and decomposition apparatus for nucleic acid polymer
US9358292B2 (en) * 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US20110045081A1 (en) * 2007-10-12 2011-02-24 Benedikt Steitz Magnetic, paramagnetic and/or superparamagnetic nanoparticles
US20090146065A1 (en) * 2007-12-07 2009-06-11 General Electric Company Scintillator materials based on lanthanide silicates or lanthanide phosphates, and related methods and articles
TWI458512B (zh) 2008-02-21 2014-11-01 Immunolight Llc 利用電漿子增強之光譜療法（ｐｅｐｓｔ）及激子－電漿增強之光療法〈epep〉治療細胞增生病症之組合物及產生自體疫苗之系統
US9011913B2 (en) * 2008-04-04 2015-04-21 The Regents Of The University Of California Use of functionalized magnetic nanoparticles in cancer detection and treatment
CN105288619A (zh) 2008-04-04 2016-02-03 免疫之光有限责任公司 用于原位光生物调节的非侵入性***和方法
EP2499677B1 (fr) * 2009-11-10 2022-03-30 Immunolight, LLC Système de conversion ascendante pour la production de lumière pour le traitement d'un désordre lié à la prolifération cellulaire
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US20110311970A1 (en) * 2010-04-14 2011-12-22 Shachaf Catherine M Compositions and methods for intracellular analyte analysis
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
EP2729175B1 (fr) 2011-07-08 2021-12-01 Duke University Appareil pour stimulation lumineuse dans un milieu
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
WO2013035739A1 (fr) * 2011-09-05 2013-03-14 株式会社Ihi Matériau de thermothérapie, système de thermothérapie et procédé de thermothérapie
ES2669561T3 (es) * 2012-02-17 2018-05-28 University Of Georgia Research Foundation, Inc. Nanopartículas para el transporte mitocondrial de agentes
JP2015521054A (ja) 2012-06-05 2015-07-27 カプリコール，インコーポレイテッド 心臓組織から心臓幹細胞を作製するための最適化方法および心臓治療におけるそれらの使用
WO2014028493A2 (fr) 2012-08-13 2014-02-20 Cedars-Sinai Medical Center Exosomes et acides micro-ribonucléiques pour la régénération de tissus
WO2015183346A2 (fr) * 2014-01-31 2015-12-03 Washington University Imagerie et traitement de conditions pathophysiologiques par rayonnement cerenkov
US10398663B2 (en) * 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US9974870B2 (en) 2014-06-09 2018-05-22 Washington University Compositions and methods for treatment and imaging using nanoparticles
WO2016054591A1 (fr) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cellules dérivées de la cardiosphère et exosomes sécrétés par ces cellules dans le traitement d'une dystrophie musculaire
US11123366B1 (en) * 2014-12-15 2021-09-21 Children's Hospital Of Orange County Methods, materials, and systems for treating injuries to the central nervous system using light emitting nanoparticles
CN118286421A (zh) 2015-05-28 2024-07-05 纳米生物技术公司 用作治疗性疫苗的纳米粒子
EP3402543B1 (fr) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cellules dérivées de cardiosphères et exosomes sécrétés par ces cellules dans le traitement d'une insuffisance cardiaque à fraction d'éjection préservée
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (fr) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cellules dérivées de cardiosphères et leurs vésicules extracellulaires pour retarder ou inverser le vieillissement et des troubles liés à l'âge
EP3612191A4 (fr) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center Méthodes et compositions pour traiter une dystrophie musculaire squelettique
EP3727351A4 (fr) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center Vésicules extracellulaires modifiées pour une administration tissulaire améliorée

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514481B1 (en) * 1999-11-22 2003-02-04 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
EP2343047B2 (fr) * 2000-02-08 2021-03-17 Rice University Nanoparticules actives optiquement à utiliser dans les procédés thérapeutiques et de diagnostic
CA2407899C (fr) * 2000-05-05 2010-11-23 Bayer Aktiengesellschaft Nanoparticules dopees servant de marqueurs biologiques
US6548264B1 (en) * 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
US20020155507A1 (en) * 2000-10-06 2002-10-24 Bruchez Marcel P. Cells having a spectral signature, and methods of preparation and use thereof
US6649138B2 (en) * 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
US20030191458A1 (en) * 2002-04-03 2003-10-09 Cornelius Diamond Light-activated drug delivery method and device
NZ541793A (en) * 2003-01-24 2008-11-28 Univ New York State Res Found Ceramic based nanoparticles for entrapping photosensitive drug/dye for photodynamic therapy
FR2869803B1 (fr) * 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations

Also Published As

Publication number Publication date
WO2006051198A1 (fr) 2006-05-18
US20070292353A1 (en) 2007-12-20
EP1807115A1 (fr) 2007-07-18
JP2008519014A (ja) 2008-06-05
FR2877571A1 (fr) 2006-05-12
JP5224814B2 (ja) 2013-07-03

Similar Documents

Publication Publication Date Title
FR2877571B1 (fr) Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
FR2886056B1 (fr) Dispositif d'affichage avec des couches de nanoparticules de metal photo-absorbantes
FR2884516B1 (fr) Antagonistes npy, preparation et utilisations
DE502006005914D1 (de) Sen im körperinneren
EG24951A (en) Piperazin derivatives & their use in controlling pests.
ZA200708692B (en) Nanoparticle/active ingredient conjugate
DE602005004144D1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mitteln
HK1103073A1 (en) Substituted diaza-spiro-[5.5-undecane derivatives and their use as neurokinin antagonists
IL173445A0 (en) 6-(1,1-difluoroalkyl)-4-aminopicolinates and their use as herbicides
Vehmasvaara Ensihoitotyön fyysinen kuormittavuus ja ensihoitajien työkyvyn fyysisiä edellytyksiä arvioivan testistön kehittäminen
IL177759A0 (en) Cospeptin, cosmedin and their uses
WO2006077189A3 (fr) Derives de 6-azo-5,5'-dihydroxy-7,7'-disulfo-2,2'-dinaphtylamine
EP1635775A4 (fr) Emulsion cosmetique stable avec polyamide
Kattainen Pitkittäistutkimus sepelvaltimoiden ohitusleikkaus-ja pallolaajennuspotilaiden terveyteen liittyvästä elämänlaadusta
Kritzer Vasubandhu and the Yogacarabhumi: Yogacara elements in the Abhidharmakosabhasya
FR2868582B3 (fr) Detecteur d'encre invisible portatif
Nation Insect Development and Evolution
Cirasuolo AGN outflows and galaxy formation
Hamilton Leadership through dialogue: talking and working together in new ways
Langkopf Web NFA Batch 6: Sites 86 90 115 137 140 150 152 153 and 191.
Yan E-commerce Patterns
Taki In the spirit of teamwork.
West Hunting: A photodocumentary
Rashad Sunnatology and Its Detail Structure
Mousavian Jurisprudential Explanation of Free-Interest Banking (Iranian and Jordanian Models)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

ST Notification of lapse

Effective date: 20180731